Phase I study of LDK378 in pediatric malignancies with a genetic alteration in ALK

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-002074-31

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Estimate the MTD and/or RDE of LDK378 as a single agent when administered orally to pediatric patients with ALK-activated tumors in the fasted and fed state


Critère d'inclusion

  • malignancies characterized by genetic abnormalities in anaplastic lymphoma kinase (ALK)